A study to evaluate the effect of immunomodulators and other factors on therapeutic effectiveness, tolerability and adherence in patients with Crohn'S Disease and Ulcerative Colitis: An Australian Population- Based Registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
Indications Crohn's disease; Ulcerative colitis
Focus Adverse reactions; Therapeutic Use
Acronyms PANIC

Most Recent Events

20 Jun 2021 Results published in the Alimentary Pharmacology and Therapeutics
10 Jul 2020 New trial record
19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight